CAJ | 학술논문

目的：观察奥氮平治疗中、高致吐性化疗药物所致恶心、呕吐的疗效和不良反应。方法：对80例应用中、高致吐性化疗药物的患者，随机分为干预组（ IG）和对照组（CG），每组40例。对照组给予常规药物止吐，干预组在常规止吐药物的基础上加用奥氮平5mg，每晚口服。以上给药方案的时间与化疗时间一致。比较两组控制急性和延迟性恶心、呕吐的疗效差别及不良反应。结果：干预组和对照组急性恶心、呕吐的发生率分别为17.5%（7/40）和22.5%（9/40，P ﹥0.05）；迟发性恶心、呕吐的发生率分别为25.0%（10/40）和65%（26/40，P ﹤0.05）。治疗过程中的不良反应主要为嗜睡（32.5%和25.0%）、头晕（17.5%和16.7%）、水肿（12.5%和15.0%）、便秘（30.0%和35.0%），两组不良反应发生率没有统计学差异。结论：奥氮平对延迟性恶心、呕吐的缓解率更优，且患者的不良反应可以耐受，具有临床推广价值。
목적：관찰오담평치료중、고치토성화료약물소치악심、구토적료효화불량반응。방법：대80례응용중、고치토성화료약물적환자，수궤분위간예조（ IG）화대조조（CG），매조40례。대조조급여상규약물지토，간예조재상규지토약물적기출상가용오담평5mg，매만구복。이상급약방안적시간여화료시간일치。비교량조공제급성화연지성악심、구토적료효차별급불량반응。결과：간예조화대조조급성악심、구토적발생솔분별위17.5%（7/40）화22.5%（9/40，P ﹥0.05）；지발성악심、구토적발생솔분별위25.0%（10/40）화65%（26/40，P ﹤0.05）。치료과정중적불량반응주요위기수（32.5%화25.0%）、두훈（17.5%화16.7%）、수종（12.5%화15.0%）、편비（30.0%화35.0%），량조불량반응발생솔몰유통계학차이。결론：오담평대연지성악심、구토적완해솔경우，차환자적불량반응가이내수，구유림상추엄개치。
To observe the clinical effect and adverse reactions of olanzapine in the prevention of high and moderate emetic risk chemotherapy - induced nausea and vomiting. Methods:Eighty patients receiving highly or moderately emetogenic chemotherapy were randomly assigned to intervention group(IG)or control group(CG). The patients in CG were given routine antiemetic drugs,while in IG were given olanzapine 5mg orally every night combined with routine antiemetic drugs. The time of drug administration was in keeping of cancer chemotherapy time. Results:Acute nausea and vomiting rates of the IG and CG were 17. 5%(7 / 40)and 22. 5%(9 / 40)respectively,there was no statistical significance(P ﹥ 0. 05),delayed nausea and vomiting rate were 25. 0%(10 / 40)and 65%(26 / 40)respec-tively,there was statistical significance(P ﹤ 0. 05). The adverse reactions during chemotherapy were drowsiness (32. 5% and 25. 0% ,respectively),swirl(17. 5% and 16. 7% ,respectively),edema(12. 5% and 15. 0% ,respec-tively),constipation(30. 0% and 35. 0% ,respectively). There were no statistical significances(P ﹥ 0. 05). Conclu-sion:Olanzapine can improve the response of nausea and vomiting in patients receiving the highly or moderately eme-togenic chemotherapy comparing with the standard therapy of antiemesis,and have no significant side effects. Olanzap-ine is a safe and efficient drug for prevention of CINV.